Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma

Détails

ID Serval
serval:BIB_0FA57E0A88C9
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma
Périodique
Journal of Immunology
Auteur(s)
Dunbar  P. R., Chen  J. L., Chao  D., Rust  N., Teisserenc  H., Ogg  G. S., Romero  P., Weynants  P., Cerundolo  V.
ISSN
0022-1767 (Print)
Statut éditorial
Publié
Date de publication
06/1999
Volume
162
Numéro
12
Pages
6959-62
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Jun 15
Résumé
Adoptive immunotherapy using CTL has provided some clinical benefit to patients with metastatic melanoma. Use of cloned CTL of known specificity might improve clinical effect, but technical difficulties have limited exploration of this possibility. We have used fluorescence-driven cell sorting to clone tumor-specific CTL after staining with tetrameric MHC class I/peptide complexes. CTL specific for the melanoma Ags melan-A, tyrosinase, and MAGE3 were cloned from the peripheral blood, tumor-infiltrated lymph nodes, and skin metastases of five patients. Clones were isolated and characterized in as little as 6 weeks, much faster than is possible with previous techniques. We show that these CTL clones express markers compatible with immunotherapeutic use in melanoma, including the cutaneous lymphocyte Ag, which is associated with homing to skin.
Mots-clé
Adult Aged Antigens, Neoplasm/*immunology/metabolism Clone Cells Epitopes, T-Lymphocyte/*immunology/metabolism Female HLA-A2 Antigen/immunology/metabolism Humans Immunotherapy, Adoptive/*methods Male Melanoma/*immunology/pathology/*therapy Middle Aged Neoplasm Proteins/immunology/metabolism Oligopeptides/chemical synthesis/immunology/metabolism T-Lymphocytes, Cytotoxic/immunology/pathology/*transplantation Tumor Cells, Cultured
Pubmed
Web of science
Création de la notice
28/01/2008 12:27
Dernière modification de la notice
20/08/2019 13:36
Données d'usage